The effects of COX-2 anti-inflammatory drugs on soft tissue healing: A review of the literature

Journal of Biological Regulators and Homeostatic Agents

Volumn 24, Issue 2, 2010, Pages 107-114

  Randelli, Pietro ^a   Randelli, F ^a   Cabitza, P ^a   Vaienti, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti inflammatory drugs; Cyclo oxygenase 2 inhibitors; Tendon healing

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PARECOXIB; ROFECOXIB; VALDECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

BONE GROWTH; BONE MATURATION; BONE MINERALIZATION; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEALING; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LIGAMENT LESION; NONHUMAN; REVIEW; SOFT TISSUE HEALING; TENDON LESION; ANIMAL; EDITORIAL; SAFETY; TENDINITIS; WOUND HEALING;

ANIMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PYRAZOLES; SAFETY; SULFONAMIDES; TENDINOPATHY; WOUND HEALING;

EID: 77955875720     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Warden SJ. Cyclo-oxygenase-2 inhibitors: beneficial or detrimental for athletes with acute musculoskeletal injuries? Sports Med 2005; 35:271-83.
2. Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop 2002; 31:445-51.
3. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. Jama 2003; 290:2411-18.
4. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999; 274:22903-06.
5. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-17.
6. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997; 49:15-19. (Pubitemid 27314722)
7. Lipsky PE. Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop 1999; 28:8-12.
8. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995; 50:1535-42.
9. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol (S) 1997; 49:6-8.
10. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A:167-70.
11. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40:124-32.
12. Weber EW, Slappendel R, Durieux ME, Dirksen R, van der Heide H, Spruit M. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 2003; 20:963-66.
13. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27:1876-1883.
14. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96:1019-27.
15. Simon AM, Manigrasso MB, O'Connor JP. Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002; 17:963-76.
16. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002; 109:1405-15.
17. Chikazu D, Tomizuka K, Ogasawara T, et al. Cyclooxygenase-2 activity is essential for the osseointegration of dental implants. Int J Oral Maxillofac Surg 2007; 36:441-6.
18. Forslund C, Bylander B, Aspenberg P. Indomethacin and celecoxib improve tendon healing in rats. Acta Orthop Scand 2003; 74:465-9.
19. Virchenko O, Skoglund B, Aspenberg P. Parecoxib impairs early tendon repair but improves later remodeling. Am J Sports Med 2004; 32:1743-7.
20. Forslund C. BMP treatment for improving tendon repair. Studies on rat and rabbit Achilles tendons. Acta Orthop Scand Suppl 2003; 74:1-30.
21. Macias D, Ganan Y, Sampath TK, Piedra ME, Ros MA, Hurle JM. Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development 1997; 124: 1109-17.
22. Dimmen S, Engebretsen L, Nordsletten L, Madsen JE. Negative effects of parecoxib and indomethacin on tendon healing: an experimental study in rats. Knee Surg Sports Traumatol Arthrosc 2009; 17:835-9.
23. Elder CL, Dahners LE, Weinhold PS. A cyclooxygenase-2 inhibitor impairs ligament healing in the rat. Am J Sports Med 2001; 29:801-5.
24. Hanson CA, Weinhold PS, Afshari HM, Dahners LE. The effect of analgesic agents on the healing rat medial collateral ligament. Am J Sports Med 2005; 33:674-9.
25. Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing. Am J Sports Med 2006; 34: 362-9.
26. Rodeo SA, Arnoczky SP, Torzilli PA, Hidaka C, Warren RF. Tendon-healing in a bone tunnel. A biomechanical and histological study in the dog. J Bone Joint Surg Am 1993; 75:1795-803.
27. Ferry ST, Dahners LE, Afshari HM, Weinhold PS. The effects of common anti-inflammatory drugs on the healing rat patellar tendon. Am J Sports Med 2007; 35:1326-33.
28. Dimmen S, Nordsletten L, Engebretsen L, Steen H, Madsen JE. The effect of parecoxib and indomethacin on tendon-to-bone healing in a bone tunnel: an experimental study in rats. J Bone Joint Surg Br 2009; 91:259-63.
29. Kobayashi M, Watanabe N, Oshima Y, Kajikawa Y, Kawata M, Kubo T. The fate of host and graft cells in early healing of bone tunnel after tendon graft. Am J Sports Med 2005; 33:1892-7.
30. Lin CH, Jee WS, Ma YF, Setterberg RB. Early effects of prostaglandin E2 on bone formation and resorption in different bone sites of rats. Bone 1995; 17:255-9.
31. Jee WS, Ueno K, Kimmel DB, Woodbury DM, Price P, Woodbury LA. The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E2. Bone 1987; 8:171-8.
32. Nefussi JR, Baron R. PGE2 stimulates both resorption and formation of bone in vitro: differential responses of the periosteum and the endosteum in fetal rat long bone cultures. Anat Rec 1985; 211:9-16.
33. O'Brien M. Functional anatomy and physiology of tendons. Clin Sports Med 1992; 11:505-20.
34. Gelberman RH, Amiel D, Harwood F. Genetic expression for type I procollagen in the early stages of flexor tendon healing. J Hand Surg [Am] 1992; 17: 551-8.
35. Leadbetter WB. Cell-matrix response in tendon injury. Clin Sports Med 1992; 11:533-78.
36. Tsai WC, Hsu CC, Chou SW, Chung CY, Chen J, Pang JH. Effects of celecoxib on migration, proliferation and collagen expression of tendon cells. Connect Tissue Res 2007; 48:46-51. (Pubitemid 46371978)
37. Walsh PM. In Physician's Desk References, 58th ed. (Thomson Healthcare, Montvale, NJ). 2004.
38. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38:225-42.
39. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2003; 42:545-56.
40. Paulson SK, Hribar JD, Liu NW, et al. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28:308-14.
41. Paulson SK, Zhang JY, Breau AP, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000; 28:514-21.
42. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-102.
43. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2:879-90.
44. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-7.
45. Vane J, Corin RE. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg 2003; 26:571-8.
46. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-81.
47. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751-6.
48. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163:481-6. (Pubitemid 36241027)
49. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 2000; 284: 1247-55.
50. Moorman CT 3rd, Kukreti U, Fenton DC, Belkoff SM. The early effect of Ibuprofen on the mechanical properties of healing medial collateral ligament. Am J Sports Med 1999; 27:738-41.
51. Dahners LE, Mullis BH. Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing. J Am Acad Orthop Surg 2004; 12: 139-43.